Lineage Cell Therapeutics Inc (LCTX)’s financial ratios: A comprehensive overview

In other words, the price has increased by $0.0000 from its previous closing price. On the day, 502420 shares were traded. LCTX stock price reached its highest trading level at $1.0800 during the session, while it also had its lowest trading level at $1.0301.

Ratios:

For a better understanding of LCTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.74 and its Current Ratio is at 2.74. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.03.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on November 02, 2022, initiated with a Outperform rating and assigned the stock a target price of $5.

On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.

On August 19, 2021, Noble Capital Markets started tracking the stock assigning a Outperform rating and target price of $8.Noble Capital Markets initiated its Outperform rating on August 19, 2021, with a $8 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 08 when BAILEY DON M bought 96,155 shares for $1.04 per share. The transaction valued at 100,001 led to the insider holds 158,801 shares of the business.

BROADWOOD PARTNERS, L.P. bought 6,730,770 shares of LCTX for $7,000,001 on Feb 06. The Director now owns 41,666,255 shares after completing the transaction at $1.04 per share. On Dec 29, another insider, Jayasuriya Anula, who serves as the Director of the company, bought 10,000 shares for $1.09 each. As a result, the insider paid 10,900 and bolstered with 10,000 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 196.02M and an Enterprise Value of 157.77M. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.35 while its Price-to-Book (P/B) ratio in mrq is 2.67. Its current Enterprise Value per Revenue stands at 17.99 whereas that against EBITDA is -6.49.

Stock Price History:

Over the past 52 weeks, LCTX has reached a high of $1.57, while it has fallen to a 52-week low of $0.84. The 50-Day Moving Average of the stock is 1.0802, while the 200-Day Moving Average is calculated to be 1.2228.

Shares Statistics:

Over the past 3-months, LCTX traded about 789.52K shares per day on average, while over the past 10 days, LCTX traded about 527.63k shares per day. A total of 188.48M shares are outstanding, with a floating share count of 187.35M. Insiders hold about 0.60% of the company’s shares, while institutions hold 48.00% stake in the company. Shares short for LCTX as of Feb 15, 2024 were 10.04M with a Short Ratio of 12.71, compared to 7.88M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.32% and a Short% of Float of 7.17%.

Earnings Estimates

Current recommendations for the stock of the company come from 7 analysts. On average, analysts expect EPS of -$0.04 for the current quarter, with a high estimate of $0 and a low estimate of -$0.05, while EPS last year was -$0.03. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.03 and low estimates of -$0.06.

Analysts are recommending an EPS of between -$0.1 and -$0.15 for the fiscal current year, implying an average EPS of -$0.14. EPS for the following year is -$0.12, with 7 analysts recommending between -$0.02 and -$0.22.

Revenue Estimates

A total of 7 analysts have provided revenue estimates for LCTX’s current fiscal year. The highest revenue estimate was $17.4M, while the lowest revenue estimate was $6.9M, resulting in an average revenue estimate of $9.5M. In the same quarter a year ago, actual revenue was $14.7M, down -35.40% from the average estimate.

Most Popular

[the_ad id="945"]